A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection

Retina

Volumn 29, Issue 10, 2009, Pages 1409-1417

  Lee, Kihwang ^a   Yang, Hongseok ^b   Lim, Hunsub ^b   Lew, Ho Min ^b  

^a Department of Opthalmology

^b Ajou University Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; RETINA BLOOD VESSEL OCCLUSION; STROKE; SUBRETINAL NEOVASCULARIZATION; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; INJECTION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RETINA DISEASE; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; HYPERTENSION; INJECTIONS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 73349109184     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b21056     Document Type: Article

References (28)

1. Adamis AP, Aiello LP, D'Amato Ra. Angiogenesis and ophthalmic disease. Angiogenesis 1999;3:9-14.
2. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25: 111-118.
3. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
4. Kernt M, Neubauer A, Kamik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 2007;85:119-120. (Pubitemid 46140172)
5. Ziemssen F, Zhu Q, Peters S, et al. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2008 Apr 17 [Epub ahead of print].
6. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87.
7. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
8. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 2009;23:181-185.
9. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007;27:1044-1047.
10. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-811.
11. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-861.
12. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008;28:1053-1060.
13. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO Study. Retina 2007;27: 141-149.
14. Krebs I, Lie S, Stolba U, Zeiler F, Felke S, Binder S. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol 2008 Oct 17 [Epub ahead of print].
15. Klein BE, Klein R, Knudtson MD. Intraocular pressure and systemic blood pressure: longitudinal perspective: the Beaver Dam Eye Study. Br J Ophthalmol 2005;89:284-287.
16. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY. Endothelial damage and angiogenesis in hyper- tensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003;16:11-20.
17. Yang R, Ogasawara AK, Zioncheck TF, et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002;39:815-820.
18. Battegay EJ, de Miguel LS, Petrimpol M, Humar R. Effects of anti-hypertensive drugs on vessel rarefaction. Curr Opin Pharmacol 2007;7:151-157.
19. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004;7:193-201.
20. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
21. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008;19:927-934.
22. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930-934.
23. Azuara-Blanco A, Harris A, Cantor LB, Abreu MM, Weinland M. Effects of short-term increase of intraocular pressure on optic disc cupping. Br J Ophthalmol 1998;82:880-883.
24. Acott TS, Kelley MJ. Extracellular matrix in the trabecular meshwork. Exp Eye Res 2008;86:543-561.
25. Bradley JMB, Kelley MJ, Zhu X, Anderssohn AM, Alexander JP, Acott TS. Effects of mechanical stretching on trabecular matrix metalloproteinases. Invest Ophthalmol Vis Sci 2001; 42:1505-1513.
26. Vaajanen A, Mervaala E, Oksala O, Vapaatalo H. Is there a relationship between blood pressure and intraocular pressure? An experimental study in hypertensive rats. Curr Eye Res 2008;33:325-332.
27. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;33:S26-S34.
28. Ceyhan M, Gunaydin S, Yorgancioglu C, Zorlutuna Y, Uluoglu C, Zengil H. Comparison of circadian rhythm characteristics of blood pressure and heart rate in patients before and after elective coronary artery bypass surgery. Chronobiol Int 2003;20:337-349.